Differential Endocrine and Metabolic Effects of Testosterone Suppressive Agents in Transgender Women

Endocrine Practice
August 2020, Vol. 26, No. 8, pp. 883-890


Objective: Suppression of testosterone secretion and/or action in transgender women using cyproterone acetate (CPA), spironolactone, or gonadotropin-releasing hormone analogues (GA) is achieved through various mechanisms. Our objective was to characterize possible differential effects of these compounds on metabolic and endocrine variables.